Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and CymbaltaGBI Research
November 22, 2011
240 Pages - SKU: XGBR6690800
Additional InformationGBI Research, the leading business intelligence provider, has released its latest research, “Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta”, which provides insights into the global pain management therapeutics market and market forecasts until 2017. The report provides an in-depth analysis of the top eight therapeutic indications for which pain management medications are prescribed, including fibromyalgia, neuropathic pain, migraine, cancer pain, osteoarthritis pain, rheumatoid arthritis pain, low back pain and post-operative pain. The report also examines the global pain management treatment usage patterns for the covered indications. In addition, the report also includes insights into the pain management R&D pipeline.
The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.
Global Pain Management Therapeutics Market to Witnesses Moderate Growth as Generic Share Continues to Rise
In 2010, the global pain management market was worth approximately $28.6 billion, representing a compound annual growth rate (CAGR) of 5.3% between 2002 and 2010. By 2017, the global pain management market is estimated to reach $35.1 billion, indicating a CAGR of 3.0% between 2010 and 2017. The major reason behind the decline in the growth rate is the decline in the annual cost of treating pain in different indications during 2010-2017. Although the market for management is highly competitive, blockbuster sales of Lyrica (pregabalin) and Cymbalta (duloxetine HCl) coupled with improved diagnosis of pain indications such as fibromyalgia and neuropathic pain are expected to drive the market in the future.
Pain Management Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
Source: GBI Research, American Academy of Pain Medicine, the American Pain Society, American Chronic Pain Association, National Fibromyalgia Association, Arthritis Association, Cancer Association
The global pain management market is expected to witness a series of patent expiries between 2009 and 2016, which includes some top selling drugs such as Cymbalta, Lyrica and Celebrex (celecoxib). While the current pain management market has a healthy pipeline and prospects for growth in the future, these factors will not be able to completely offset the challenge from generic competition. Therefore, while the pipeline ensures potential for attractive growth in the long term, Unmet Need for Better Management of Pain and Potential for Future Growth is Driving Companies to Invest in Research and Development
The research and development (R&D) pipeline for pain management is moderately healthy due to the presence of about 282 programs. These programs study drug candidates for the treatment of neuropathic pain and pain associated with fibromyalgia, cancer, migraine and osteoarthritis, rheumatoid arthritis, low back pain and post-operative pain.
Pain Management Therapeutics Market, Global, R&D Pipeline by Indication, 2010
Source: GBI Research, Company Websites, ClinicalTrials.gov
Nevertheless, the products in the pipeline do not look promising and may not provide better efficacy and safety levels compared to the drugs currently in the market. The pipeline is a mix of first-in-class and me-too products. The success of the first-in-class products will determine the future prospects for the industry. The high level of R&D activity indicates that the pain management market has potential for growth.
Lyrica and Cymbalta Drive the Pain Management Market
Lyrica (pregabalin) is the branded anticonvulsant product of Pfizer. Lyrica is indicated for the treatment of epilepsy, fibromyalgia and neuropathic pain. Lyrica, along with Neurontin (gabapentin), is the first line of therapy for the treatment of neuropathic pain, especially when tricyclic antidepressants are contraindicated. Lyrica is the only anticonvulsant which has been approved for the treatment of fibromyalgia. Lyrica generated revenue of $2.6 billion and $2.8 billion for Pfizer in 2008 and 2009 respectively. Eli Lilly’s Cymbalta is another major drug approved for fibromyalgia, chronic osteoarthritis pain and chronic low back pain. Cymbalta registered revenue of $2.6 billion and $3 billion in 2008 and 2009 respectively.
More Pain reports by GBI Research
Prescribing Trends in Opioids - Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain Management by GBI Research
Prescribing Trends in Opioids - Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain ManagementSummaryGBI Research, the leading business intelligence provider, has ...
Growth Strategies for Supergenerics Organizations - Opportunities in Addressing Unmet Medical Needs and Providing Cost-Effective Solutions for Product Development in Emerging Markets by GBI Research
Growth Strategies for Supergenerics Organizations - Opportunities in Addressing Unmet Medical Needs and Providing Cost-Effective Solutions for Product Development in Emerging MarketsSummaryGBI Research, a leading ...
The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges by GBI ResearchSee all reports like this >>
The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates ChallengesSummaryGBI Research has released its research - “The ...
We can help you find what you need. Call us or write us:
Need help in your search?